OMIM# | 22930 | 615595 | 603485 | 255125 | 614585 | 616860 and 616859 | 605711 | 614299 | 615330 | 616370 | 613621 | 301310 | 616854 |
Disease | Friedreich ataxia (FRDA) | Combined oxidative phosphorylation deficiency 19 | Infantile complex II/III deficiency (IMC23D) | Myopathy with lactic acidosis, hereditary | mitochondrial muscle myopathy | 616860: Anemia, sideroblastic, 3, pyridoxine-616859: refractory Spasticity, childhood- | Multiple mitochondrial dysfunctions syndrome 1 | Multiple mitochondrial dysfunctions syndrome 2 | Multiple mitochondrial dysfunctions syndrome 3 | Multiple mitochondrial dysfunctions syndrome 4 | Mitochondrial complex I deficiency | Sidroblastic anemia with ataxia | Even-plus syndrome |
Year | 1996 | 2013 | 2014 | 2008 | 2014 | 2007 and 2011 | 2011 | 2011 | 2013 | 2015 | 2010 | 1999 | 2015 |
Pathway defect | Core [Fe-S] assembly | Core [Fe-S] assembly | Core [Fe-S] assembly | Core [Fe-S] assembly | Core [Fe-S] assembly | [Fe-S] transfer to specific recipients | [Fe-S] transfer to specific recipients | [Fe-S] transfer to specific recipients | [Fe4-S4] assembly | [Fe4-S4] assembly | Mitochondrial translation; complex I assembly | Mitochondrial export | Mitochondrial iron import |
Number of patients/Prevalence | 1:50000 | 2 | 3 | 25 | 1 | 5 | 20 | 3 | 2 | 6 | 7 | 22 | 3 |
Age of onset | Childhood-Adult (usually 2nd decade) | Neonatal | Infantile | Childhood | Childhood | Adult and childhood | neonatal and infantile | Infantile | Neonatal | Infantile | Infantile | Childhood | Prenatal |
Origin | Panethnic | Lebanon and Syria | Canada | Sweden and Norway | Morocco | Italy and China | Mexico, Germany, Serbia, Romania, Pakistan | India, Australia, Africa | Morocco | Saudi | Argentina, Germany, Canada, Australia, Netherlands | USA | Chile and Korea |
Clinical hints | Ataxia, dysarthria, muscle weakness, spasticity in the lower limbs, scoliosis, bladder dysfunction, absent lower limb reflexes, and loss of position and vibration sense, cardiomyopathy, DM | Hypotonia, respiratory distress | Hypotonia, respiratory distress, seizure, multisystem organ failure | Muscle weakness, exercise intolerance and cardiomyopathy | Severe proximal lower limb weakness and muscle cramps | 616860: Sideroblastic anemia, hepatosplenomegaly and jaundice 616859: Spastic paraplegia, spinal lesion, and optic atrophy | Hypotonia, respiratory distress, seizure, Neurologic regression pulmonary hypertension, lethargy, poor feeding, White matter lesions seen on brain imaging | Hypotonia, respiratory distress, seizure, Neurologic regression, lethargy, poor feeding, optic atrophy, white matter lesions seen on brain imaging | Severe hypotonia, generalized muscle weakness, absent primitive reflexes, microcephaly and dysmorphic features (retrognathia, high palate, widely spaced nipples, arthrogryposis, cerebral atrophy and polymicrogyria on Brain MRI | Neuroregression, developmental delay, nystagmus with optic atrophy and diffuse white matter disease of the brain and spine | Hypotonia, muscle weakness, muscle atrophy exercise intolerance Muscle biopsy shows abnormal mitochondria, developmental delay, neuroregression, seizure, white matter lesions seen on brain imaging | Sidroblastic anemia and ataxia | EVEN-PLUS syndrome is characterized by short stature, vertebral and epiphyseal changes, microtia, midface hypoplasia with flat nose and triangular nares, cardiac malformations, and other findings including anal atresia, hypodontia, and aplasia cutis. The features overlap those reported in patients with CODAS syndrome |
Biochemical hints | None | Lactic acidosis, metabolic acidosis, high liver enzymes low complexes I-IV in the muscle | Lactic acidosis, metabolic acidosis, high CK level and high liver enzymes, DIC picture, low complexes II and III in the muscle | Lactic acidosis, Myoglobinuria Histopathology showed succinate dehydrogenase and cytochrome c oxidase (COX) deficienc | Lactic acidosis, myoglobinuria and low complexes I, II and III in the muscle | 616860: hypochromic microcytic anemia, increase ferritin level, ringed sideroblasts on bone marrow aspirate | Hyperglycinemia, metabolic acidosis, lactic acidosis, Increased urinary 2-hydroxybutyrate, Decreased activity of pyruvate dehydrogenase complex, low complexes I and II in the muscle | same as NFU1 gene defect | Hyperglycinemia, metabolic acidosis, lactic acidosis | Hyperglycinemia, metabolic acidosis, lactic acidosis | hypoglycemia, lactic acidosis, low complex I in the muscle | Increased free erythrocyte protoporphyrin, hypochromic microcytic anemia, ringed sideroblasts on bone marrow aspirate | Not specific |
Mutation reported | 90 % have expanded GAA repeat in intron 1 of FXN gene* | Missense mutation c.203G>T, p.Arg68Lys | Missense mutation c.251G>A, p.Arg72Gln | Splicing defect IVS5 + 382G>C, heterozygosity for the splicing defect and the missense mutation c.149G>A, p.Gly50Glu | homozygous mutation c.1A>T | 616860: A> G homozygous transition 616859: Homozygous deletion c.151_153delAAG, p.K51del or compound heterozygosity for p.K51del and 8bp insertion | A homozygous missense mutation, c.545G>A(p.Arg182Gln), compound heterozygous for aforementioned mutation and a splice-site (c.545+5G>A) mutation, compound heterozygous mutation (g.69400462C>A, p.Gly208Cys); g.69592691_ 69648327del, [?]) compound heterozygous mutation (c.544C>T, [?], p.Arg182Trp);[?]), (c. 565G>A, p. Gly189Arg);[568G>A],;[Gly190 Arg]), (c.[544C>T];[?], p.[Arg182Trp];[?]), homozygous frameshift mutation c.302+3A>G (p.Val56Glyfs*9), compound heterozygous mutation (c.62G>C, p.Arg21Pro); (c.622G>T, p.Gly208Cys) | (c.136C4T, p.R46X) | (c.941A > C, p.Gln314Pro) | (c.229G>A, p.Gly77Ser) | Homozygous missense mutation (c.166G>A, p.Gly56Arg), intronic mutation: c.815-27T>C or compound heterozygous for (c.166G>A, p.Gly56Arg) and other mutation | Homozygous missense mutation(c.1200T>G(p.Ile400Met), Other several mutations near to or in transmembrane domains of the ABC transporter | Compound hgetrozygous mutation (c.383A > G (p.Y128C) and c.882_883delAG (p.V296*), homozygous missense mutation (c.376C > T;p.Arg126Trp). |
Mortality | The average age of death was at 37.5 years (range, 5–71 years) | 1/2 | 2/3 | None | None | None | 20/20 | 3/3 | 2/2 | 4/6 | None | None | None |